Alembic Pharmaceuticals is currently trading at Rs. 950.00, up by 6.10 points or 0.65% from its previous closing of Rs. 943.90 on the BSE.
The scrip opened at Rs. 945.65 and has touched a high and low of Rs. 969.00 and Rs. 941.80 respectively. So far 13556 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 2 has touched a 52 week high of Rs. 984.00 on 22-Jun-2020 and a 52 week low of Rs. 436.10 on 23-Mar-2020.
Last one week high and low of the scrip stood at Rs. 969.85 and Rs. 905.00 respectively. The current market cap of the company is Rs. 17999.50 crore.
The promoters holding in the company stood at 72.97%, while Institutions and Non-Institutions held 14.40% and 12.63% respectively.
Alembic Pharmaceuticals is looking at enhancing profitability of its domestic business and expects it to grow in double digits in the current financial year (FY21) with focus on high-margin products. The company aims to grow its presence in the specialty and chronic therapy segments. The drug firm has already started witnessing an uptick in domestic business with new product strategy in place. Strong brand recall, an efficient sales force, a growing network of supportive doctors and timely product launches are the key catalysts for this business.
In 2019-20, the company’s revenues from domestic business stood at Rs 1,425 crore, a growth of 3 per cent over Rs 1,382 crore in 2018-19, and accounted for 31 per cent of the company’s overall revenues that stood at Rs 4,606 crore. The company’s international generics business, on the other hand, accounted for 54 per cent of its overall revenues in 2019-20. The segment saw a revenue growth of 39 per cent to Rs 2,473 crore in 2019-20.
Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.
